TY - JOUR
T1 - Six-year trajectories and associated factors of positive and negative symptoms in schizophrenia patients, siblings, and controls
T2 - Genetic Risk and Outcome of Psychosis (GROUP) study
AU - Habtewold, Tesfa Dejenie
AU - Tiles-Sar, Natalia
AU - Liemburg, Edith J.
AU - Sandhu, Amrit Kaur
AU - Islam, Md Atiqul
AU - Boezen, H. Marike
AU - Alizadeh, Behrooz Z.
AU - van Amelsvoort, Therese
AU - Bartels-Velthuis, Agna A.
AU - de Haan, Lieuwe
AU - Schirmbeck, Frederike
AU - Simons, Claudia J.P.
AU - van Os, Jim
AU - Bruggeman, Richard
AU - Alizadeh, Behrooz Z.
N1 - Funding Information:
Tesfa Dejenie Habtewold is supported by the scholarship for a PhD from the University of Groningen (Grant Number = 616163), Groningen, the Netherlands. This work was supported by Geestkracht programme of the Dutch Health Research Council (Zon-Mw) (Grant Number = 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck; AstraZeneca; Eli Lilly and Janssen Cilag) and, universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest; Arkin, Dijk en Duin; GGZ Rivierduinen; Erasmus Medical Centre and GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland; GGZ Drenthe; Dimence; Mediant; GGNet Warnsveld; Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen; GGZ Breburg; GGZ Oost-Brabant; Vincent van Gogh voor Geestelijke Gezondheid; Mondriaan; Virenze riagg; Zuyderland GGZ; MET ggz; Universitair Centrum Sint-Jozef Kortenberg; CAPRI University of Antwerp; PC Ziekeren Sint-Truiden; PZ Sancta Maria Sint-Truiden; GGZ Overpelt and OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht; GGZ Centraal and Delta). The sponsors have no role in designing the study, the collection, analysis, and interpretation of data, the writing of the report and the decision to submit the paper for publication.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/6/9
Y1 - 2023/6/9
N2 - Positive and negative symptoms are prominent but heterogeneous characteristics of schizophrenia spectrum disorder (SSD). Within the framework of the Genetic Risk and Outcome of Psychosis (GROUP) longitudinal cohort study, we aimed to distinguish and identify the genetic and non-genetics predictors of homogenous subgroups of the long-term course of positive and negative symptoms in SSD patients (n = 1119) and their unaffected siblings (n = 1059) in comparison to controls (n = 586). Data were collected at baseline, and after 3- and 6-year follow-ups. Group-based trajectory modeling was applied to identify latent subgroups using positive and negative symptoms or schizotypy scores. A multinomial random-effects logistic regression model was used to identify predictors of latent subgroups. Patients had decreasing, increasing, and relapsing symptoms course. Unaffected siblings and healthy controls had three to four subgroups characterized by stable, decreasing, or increasing schizotypy. PRSSCZ did not predict the latent subgroups. Baseline symptoms severity in patients, premorbid adjustment, depressive symptoms, and quality of life in siblings predicted long-term trajectories while were nonsignificant in controls. In conclusion, up to four homogenous latent subgroups of symptom course can be distinguished within patients, siblings, and controls, while non-genetic factors are the main factors associated with the latent subgroups.
AB - Positive and negative symptoms are prominent but heterogeneous characteristics of schizophrenia spectrum disorder (SSD). Within the framework of the Genetic Risk and Outcome of Psychosis (GROUP) longitudinal cohort study, we aimed to distinguish and identify the genetic and non-genetics predictors of homogenous subgroups of the long-term course of positive and negative symptoms in SSD patients (n = 1119) and their unaffected siblings (n = 1059) in comparison to controls (n = 586). Data were collected at baseline, and after 3- and 6-year follow-ups. Group-based trajectory modeling was applied to identify latent subgroups using positive and negative symptoms or schizotypy scores. A multinomial random-effects logistic regression model was used to identify predictors of latent subgroups. Patients had decreasing, increasing, and relapsing symptoms course. Unaffected siblings and healthy controls had three to four subgroups characterized by stable, decreasing, or increasing schizotypy. PRSSCZ did not predict the latent subgroups. Baseline symptoms severity in patients, premorbid adjustment, depressive symptoms, and quality of life in siblings predicted long-term trajectories while were nonsignificant in controls. In conclusion, up to four homogenous latent subgroups of symptom course can be distinguished within patients, siblings, and controls, while non-genetic factors are the main factors associated with the latent subgroups.
UR - http://www.scopus.com/inward/record.url?scp=85161635887&partnerID=8YFLogxK
U2 - 10.1038/s41598-023-36235-9
DO - 10.1038/s41598-023-36235-9
M3 - Article
C2 - 37296301
AN - SCOPUS:85161635887
SN - 2045-2322
VL - 13
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 9391
ER -